What is HC Wainwright's Forecast for CATX FY2025 Earnings?

Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Equities research analysts at HC Wainwright dropped their FY2025 earnings per share estimates for shares of Perspective Therapeutics in a research report issued on Wednesday, March 19th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($1.20) for the year, down from their prior forecast of ($1.19). HC Wainwright has a "Buy" rating and a $10.00 price objective on the stock. The consensus estimate for Perspective Therapeutics' current full-year earnings is ($0.88) per share.

Other analysts have also issued reports about the stock. Scotiabank initiated coverage on shares of Perspective Therapeutics in a research report on Friday, March 7th. They issued a "sector outperform" rating and a $15.00 price target on the stock. Bank of America lowered Perspective Therapeutics from a "buy" rating to a "neutral" rating and lowered their price target for the company from $24.00 to $5.00 in a research note on Monday, November 25th. Wedbush reiterated an "outperform" rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a research report on Monday, March 17th. Cantor Fitzgerald upgraded Perspective Therapeutics to a "strong-buy" rating in a research report on Tuesday, March 4th. Finally, Brookline Capital Management raised Perspective Therapeutics to a "strong-buy" rating in a research report on Monday, March 10th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, Perspective Therapeutics currently has an average rating of "Buy" and a consensus price target of $14.56.

Perspective Therapeutics Trading Down 2.0 %

Shares of Perspective Therapeutics stock traded down $0.05 during midday trading on Friday, hitting $2.47. The company had a trading volume of 246,214 shares, compared to its average volume of 992,000. Perspective Therapeutics has a 1-year low of $2.32 and a 1-year high of $19.05. The business's 50 day simple moving average is $3.00 and its two-hundred day simple moving average is $6.57.

Institutional Investors Weigh In On Perspective Therapeutics

A number of hedge funds have recently made changes to their positions in CATX. Charles Schwab Investment Management Inc. grew its stake in Perspective Therapeutics by 221.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 433,522 shares of the company's stock worth $5,788,000 after buying an additional 298,778 shares during the last quarter. State Street Corp grew its position in Perspective Therapeutics by 119.6% during the 3rd quarter. State Street Corp now owns 2,190,239 shares of the company's stock worth $29,240,000 after acquiring an additional 1,192,812 shares during the last quarter. Janus Henderson Group PLC increased its holdings in Perspective Therapeutics by 8.0% during the 3rd quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company's stock valued at $64,014,000 after purchasing an additional 355,685 shares in the last quarter. FMR LLC increased its holdings in Perspective Therapeutics by 3,994.9% during the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company's stock valued at $73,489,000 after purchasing an additional 5,370,392 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its position in Perspective Therapeutics by 1,302.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 47,565 shares of the company's stock valued at $635,000 after purchasing an additional 44,174 shares during the last quarter. Institutional investors and hedge funds own 54.66% of the company's stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.